The article calls for a $1 billion market cap buy out. That would closer to $11 per share.
"BioSante may fetch an acquisition price as high as $1 billion as early as the first quarter of next year if two studies of 500 women each find the drug increases desire and sexual experiences, Piros said. The data is due to be reported by the end of the year, the company said."